Literature DB >> 16228972

Morphological effects of myasthenia gravis patient sera on human muscle cells.

Steven Paul Luckman1, Geir Olve Skeie, Geir Helgeland, Nils Erik Gilhus.   

Abstract

Myasthenia gravis (MG) is caused primarily by autoantibodies against the nicotinic acetylcholine receptor (AChR), but autoantibodies to other muscle proteins may be present. Many of these proteins have structural or signalling functions, the disruption of which may affect muscle cell morphology or viability. In order to investigate the role of such autoantibodies in MG, we examined the effect of MG patient sera, of different autoantibody composition and obtained at different stages of disease severity, on primary human muscle cells. Sera from MG patients induced changes in cell morphology from typical elongated cells to an irregular phenotype, caused the formation of inclusion bodies and intracellular vesicles, and led to a disordered arrangement of actin microfilaments. Sera from the most severely affected patients also induced cell death, which did not occur via classic apoptosis. The effects were not complement-mediated and were dose- and time-dependent. As the effects observed in the cell culture system correlated with disease severity, a greater understanding of the individual factors responsible for these effects may improve our understanding of MG pathogenesis and be of value in the assessment of disease in individual patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16228972     DOI: 10.1002/mus.20443

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

1.  Mitochondrial bioenergetics in ocular fibroblasts of two myasthenia gravis cases.

Authors:  Tarin A Europa; Melissa Nel; Maribanyana R Lebeko; Jeannine M Heckmann
Journal:  IBRO Neurosci Rep       Date:  2022-04-21

2.  Thymoma in myasthenia gravis: from diagnosis to treatment.

Authors:  Fredrik Romi
Journal:  Autoimmune Dis       Date:  2011-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.